Login to Your Account

Beyond the ‘Horizant’: Xenoport adds $72M in upsized offering

By Jennifer Boggs
Managing Editor

Friday, January 24, 2014
On the heels of encouraging FDA feedback for a multiple sclerosis program and the possibility of profitability for marketed drug Horizant (gabapentin enacarbil) by the end of 2015, Xenoport Inc. is padding its coffers with a $72 million bumped-up public offering.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription